Serotonin receptors and the acute attack of migraine

Clinical Neuroscience

Volumn 5, Issue 1, 1998, Pages 18-23

  Goadsby, Peter J ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Acute attack therapies; Migraine; Serotonin receptors

Indexed keywords

5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 HYDROXYINDOLEACETIC ACID; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ANTIMIGRAINE AGENT; DIHYDROERGOTAMINE; ELETRIPTAN; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; NEUROPEPTIDE; RECEPTOR SUBTYPE; RIZATRIPTAN; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1F RECEPTOR; SEROTONIN RECEPTOR; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ACUTE DISEASE; ARTICLE; DRUG MECHANISM; HUMAN; MIGRAINE; PRIORITY JOURNAL; TRIGEMINAL NERVE; VASOCONSTRICTION;

ACUTE DISEASE; AFFERENT PATHWAYS; HUMANS; MIGRAINE DISORDERS; NEURAL INHIBITION; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; TRIGEMINAL GANGLION; VASOCONSTRICTOR AGENTS;

EID: 0031908556     PISSN: 10656766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. 1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci USA 90:408-412.
2. Anthony M, Hinterberger H, Lance JW (1967): Plasma serotonin in migraine and stress. Arch Neurol 16:544-552.
3. 1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol 345:500-508.
4. Buzzi MG, Moskowitz MA (1990): The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99:202-206.
5. Buzzi MG, Sakas DE, Moskowitz MA (1989): Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 165:251-258.
6. Buzzi MG, Moskowitz MA, Shimizu T, Heath HH (1991): Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30:1193-1200.
7. 1D antagonists, J Med Chem 37:2253-2257.
8. Connor HE, Stubbs CM, Feniuk W, Humphrey PPA (1992): Effect of sumatriptan, a selective 5-HT1-like receptor agonist, on pial vessel diameter in anaesthetised cats. J Cereb Blood Flow Metab 12:514-519.
9. Couch JR, Saper J, Meloche JP (1996): Treatment of migraine with BMS180048: response at 2 hours. Headache 36:523-530.
10. Cumberbatch MJ, Hill RG, Hargreaves RJ (1997): Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol 328:37-40.
11. Curran DA, Hinterberger H, Lance JW (1965): Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 88:997-1010.
12. Dimitriadou V, Buzzi MG, Theoharides TC, Moskowitz MA (1992): Ultrastructural evidence for neurogenically mediated changes in blood vessels of the rat dura mater and tongue following antidromic trigeminal stimulation. Neuroscience 48: 187-203.
13. Edvinsson L, Goadsby PJ (1997): Neuropeptides in headache. Eur J Neurol (in press).
14. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S (1995): Increases in plasma calcitonin generelated peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60:119-123.
15. Feindel W, Penfield W, McNaughton F (1960): The tentorial nerves and localisation of intracranial pain in man. Neurology 10:555-563.
16. IC receptor activation: A key step in the initiation of migraine? Trends Pharmacol Sci 10:307-309.
17. Friberg L, Olesen J, Iversen HK, Sperling B (1991): Migraine pain associated with middle cerebral artery dilatation: Reversal by sumatriptan. Lancet 338:13-17.
18. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Trequattrini A, Palumbo R (1995): Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15:384-390.
19. Goadsby PJ (1997): How do the currently used prophylactic agents work in migraine? Cephalalgia 17:85-92:
20. Goadsby PJ, Duckworth JW (1987): Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 253:R270-R274.
21. Goadsby PJ, Edvinsson L (1993): The trigeminovascular system and migraine: Studies characterising cerebrovascular and neuropeptide changes seen in man and cat. Ann Neurol 33:48-56.
22. Goadsby PJ, Edvinsson L (1994a): Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 117:427-434.
23. Goadsby PJ, Edvinsson L (1994b): Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34:394-399.
24. Goadsby PJ, Edvinsson L (1997): Regulation of cerebral blood flow by the parasympathetic nervous system. In Welch KMA, Caplan L, Reis DJ, Weir B, Siesjo B (eds): Primer of Cerebrovascular Diseases. San Diego: Academic Press, pp 63-66.
25. 3H]-dihydroergotamine binding sites in the cat central nervous system: Relevance to migraine. Ann Neurol 29:91-94.
26. Goadsby PJ, Hoskin KL (1996): Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)-1-D receptor agonist zolmitriptan (311C90): Are brain stem sites a therapeutic target in migraine? Pain 67:355-359.
27. Goadsby PJ, Hoskin KL (1997a): The distribution of trigeminovascular afferents in the non-human primate brain macaca nemestrina: A c-fos immunocytochemical study. J Anat 190:367-375.
28. Goadsby PJ, Hoskin KL (1997b): Is the action of serotonin in migraine due in part to inhibition of neurons in the trigeminal nucleus? Cephalalgia 17:400.
29. Goadsby PJ, Knight YE (1997): Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 17:153-158.
30. Goadsby PJ, Lipton RB (1997): A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic features, including new cases. Brain 120:193-209.
31. Goadsby PJ, Sercombe R (1996): Neurogenic regulation of cerebral blood flow: Extrinsic neural control. In Mraovitch S, Sercombe R (eds): Neurophysiological Basis of Cerebral Blood Flow Control: An Introduction. Paris: John Libbey and Co., Ltd, pp 285-322.
32. Goadsby PJ, Silberstein SD (1997): Headache. New York: Butterworth-Heinemann.
33. Goadsby PJ, Zagami AS (1991): Stimulation of the superior sagittal sinus increases metabolic activity and blood flow in certain regions of the brainstem and upper cervical spinal cord of the cat. Brain 114:1001-1011.
34. Goadsby PJ, Edvinsson L, Ekman R (1988): Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann Neurol 23:193-196.
35. Goadsby PJ, Edvinsson L, Ekman R (1990): Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28:183-187.
36. Goadsby PJ, Zagami AS, Lambert GA (1991): Neural processing of craniovascular pain: A synthesis of the central structures involved in migraine. Headache 31:365-371.
37. Goadsby PJ, Knight YE, Hoskin KL (1997): Processing of occipital pain in the caudal trigeminal nucleus: Referred pain in primary headache. Cephalalgia 17 (in press).
38. Goldstein J, Dahlof CGH, Diener H-C, Olesen J, Schellens R, Senard JM, Simard D, Steiner TJ (1996): Alniditan in the acute treatment of migraine attacks: A subcutaneous dose-finding study. Cephalalgia 16:497-502.
39. Gupta P, Brown D, Butler P, Ellis P, Grayson KL, Land GC, Macor JE, Robson SF, Wythes MJ, Shepperson NB (1995): The in vivo pharmacological profile of a 5-HT1 receptor agonist, CP122,288, a selective inhibitor of neurogenic inflammation. Br J Pharmacol 116:2385-2390.
40. 1b binding sites in rat brain membranes: Evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 243:989-1001.
41. Hartig PR, Hoyer D, Humphrey PPA, Martin GR (1996): Alignment of receptor nomenclature with the human genome: Classification of 5HT-1B and 5-HT1D receptor subtypes. Trends Pharmacol Sci 17:103-105.
42. Hoskin KL, Kaube H, Goadsby PJ (1996a): Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: A c-Fos and electrophysiology study. Brain 119:249-256.
43. Hoskin KL, Kaube H, Goadsby PJ (1996b): Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 119:1419-1428.
44. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Myelcharane EJ, Saxena PR, Humphrey PP (1994): International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 46:157-203.
45. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML (1991): Preclinical studies on the antimigraine drug, sumatriptan. Eur Neurol 31:282-290.
46. 2C receptor blockade? Life Sci 54:641-644.
47. Kaube H, Hoskin KL, Goadsby PJ (1992): Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 12:133-136.
48. Kaube H, Hoskin KL, Goadsby PJ (1993a): Sumatriptan inhibits central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 109:788-792.
49. Kaube H, Keay K, Hoskin KL, Bandler R, Goadsby PJ (1993b): Expression of c-fos-like immunoreactivity in the trigeminal nucleus caudalis and high cervical cord following stimulation of the sagittal sinus in the cat. Brain Res 629:95-102.
50. Kimball RW, Friedman AP, Vallejo E (1960): Effect of serotonin in migraine patients. Neurology (Minneapolis) 10:107-111.
51. 1B/1D receptor. Cephalalgia 17:403.
52. Lance JW, Anthony M, Hinterberger H (1967): The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7:93-102.
53. Lee WK, Limmroth V, Ayata C, Cutrer FM, Waeber C, Yu X-Y, Moskowitz MA (1995): Peripheral GABA-A receptor mediated effects of sodium valproate on durai plasma protein extravasation to substance P and trigeminal stimulation. Br J Pharmacol 116:1661-1667.
54. Lee WS, Moskowitz MA (1993): Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638, exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 626:303-305.
55. 3H]alniditan. Mol Pharmacol 50:1567-1580.
56. Limmroth V, Wermelskirchen D, Tegtmeier F, Diener HC (1997): R91274 (alniditan) blocks neurogenic inflammation in the rat meninges more effectively than sumatriptan by activation of 5HT1D-receptors. Neurology 48:A69.
57. Markowitz S, Saito K, Moskowitz MA (1987): Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J Neurosci 7:4129-4136.
58. 3H]sumatriptan binding in cat brain stem and spinal cord. Eur J Pharmacol 280:175-178.
59. Moskowitz MA (1992): Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 13:307-311.
60. Pascual J, Arco CD, Romon T, Olmo CD, Pazos A (1996): [3H] Sumatriptan binding sites in human brain: Regional-dependent labelling of 5HT1D and 5HT1F receptors. Eur J Pharmacol 295: 271-274.
61. Penfield W (1932): Operative treatment of migraine and observations on the mechanism of vascular pain. Trans Am Acad Ophthalmol Otolaryngol III:1-16.
62. Penfield W, McNaughton FL (1940): Durai headache and the innervation of the dura mater. Arch Neurol Psychiatry 44:43-75.
63. 1D subtype. Br J Pharmacol 102:191-197.
64. 1F receptor agonist, in the neurogenic durai inflammation model of migraine pain. Proc Soc Neurosci USA 22:1331.
65. Roon K, Diener HC, Ellis P, Hettiarachchi J, Poole P, Christiansen I, Ferrari MD and Olesen J (1997) CP-122,288 blocks neurogenic inflammation, but is not effective in aborting migraine attacks: results of two controlled clinical studies, Cephalalgia, 17:245.
66. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ (1995): Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in the dura mater and c-fos mRNA expression in the trigeminal nucleus caudalis of rats. Neuropharmacology 34:255-261.
67. Sicuteri F, Testi A, Anselmi B (1961): Biochemical investigations in headache: Increases in hydroxyindoleacetic acid excretion during migraine attacks. Int Arch Allergy 19:55-58.
68. Sleight AJ, Cervenka A, Peroutka SJ (1990): In vivo effects of sumatriptan (GR 43175) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 29:511-513.
69. 1B/1D receptors. Cephalalgia 17:241.
70. Villalon CM, Bom AH, Boer MOD, Heiligers JP, Saxena PR (1992): Effects of S9977 and dihydroergotamine in an animal experimental model for migraine. Pharmacol Res 25:125-137.
71. 3H]sumatriptan labels both 5-HT1D and 5HT-1F receptor bindings sites in the guinea pig brain: An autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 352:263-275.
72. Weiller C, May A, Limmroth V, Juptner M, Kaube H, Schayck RV, Coenen HH, Diener HC (1995): Brain stem activation in spontaneous human migraine attacks. Nature Med 1:658-660.
73. Wolff HG (1963): Headache and OtherHead Pain. New York: Oxford University Press.
74. 1D agonist. Cephalalgia 15(Suppl 14):174.
75. Yu X-J, Waeber C, Castanon N, Scearce K, Hen R, Macor JE, Chaveau J, Moskowitz MA (1996): 5-carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl-tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine 1B receptors. Mol Pharmacol 49:761-765.
76. Zagami AS, Goadsby PJ, Edvinsson L (1990): Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16: 69-75.